Table 3. Availability of Product Information.
| Study (First author) | Results calculated based on | Brand name n (%) | Generic name n (%) | Indications n (%) | Contraindications n (%) | Interactions n (%) |
| Carandang 1994 [10] | Distinct advertisements | Not reported | 115/127 (91) | Not reported | Not reported | Not reported |
| Chirac 1993 [11] | Distinct advertisements | Not reported | 125/141 (89) | 136/141 (96) | 97/141 (69) | Not reported |
| Mastroianni 2003 [30]* | Distinct advertisements | Not reported | 34/39 (87), 29/31 (90) | 37/39 (95), 31/31 (100) | 20/39 (51), 20/31 (64) | 20/39 (51), 21/31 (68) |
| Not reported | 17/19 (89), 18/19 (95) | 18/19 (95), 19/19 (100) | 10/19 (53), 12/19 (63) | 9/19 (47), 11/19 (58) | ||
| Not reported | 51/60 (85), 34/34 (100) | 57/60 (95), 33/34 (97) | 22/60 (37), 25/34 (74) | 22/60 (37), 25/34 (73) | ||
| Stimson 1975 [42] | Distinct advertisements. | 544/591 (92) | 255/591 (43) | Not reported | 25/591 (4) | Not reported |
| Vlassov 2001 [31] | Number of placements. | A few advertisements | 154/397(39) | 177/397 (45) | 42/397 (11) | 21/397 (5) |
| Study (First author) | Results calculated based on | Brand name n (%) | Generic name n (%) | Indications n (%) | Contraindicationsn (%) | Interactions n (%) |
| Lal 1992 [39] | No detail information was given | (100) | (84) | (80) | (10) | (3) |
| Herxheimer 1993 [14] (18 countries) | No detail information was given | Not reported | Not reported | (94),(86),(90),(94), (91),(97),(34),(93), (97),(80),(91),(94), (81),(77), (84), (40),(97),(98) | (1),(67),(21),(88), (88),(73),(35),(35), (93),(8),(33),(18), (-), (35), (22), (20),(24), (43) | Not reported |
| Lal 1997 [29] | No detail information was given | (100),(100), (100) | (89), (98), (99) | (80), (92), (97) | (13),(82), (91) | (8),(63), (38) |